Drug Trial Radar · NCT02416388
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,100
Planned (sponsor's estimate)
Start
Jan 2015
Primary completion
Jul 30, 2025
Study completion Jan 2032
Sponsor
- Lead sponsor
- University Hospital, AngersGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Apr 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 61 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
IdarubicinDrug
Induction chemotherapy : Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min) \+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
DaunorubicinDrug
Induction chemotherapy : Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min) \+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
HD CytarabineDrug
Consolidation chemotherapy course (s) : -High dose cytarabine: 3g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
CyclosporineDrug
GvHD prophylaxis post allogeneic SCT : -Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
MethotrexateDrug
GvHD prophylaxis post allogeneic SCT : -15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11
Mycophenolic acid (MPA)Drug
GvHD prophylaxis post allogeneic SCT : * 720 mg BID from D0 to D+28 for HLA-identical siblings * 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
vosaroxinDrug
Consolidation chemotherapy course (s) : -70 mg/m² on D1 and D4
ID cytarabineDrug
Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group
DexamethasoneDrug
Consolidation chemotherapy course (s) : -10 mg/12h on D1, D3 and D5
VenetoclaxDrug
Consolidation chemotherapy course (s) : Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following: * 100 mg/d on D1 to D8 (selection phase dose level 1) * or 200 mg/d on D1 to D8 (selection phase dose level 2) * or 400 mg/d on D1 to D8 (selection phase dose level 3) * or 400 mg/d on D1 to D14 (selection phase dose level 4)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 3 years
- Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IVTime frame: 100 days
- Disease free survivalTime frame: 18 months
Locations
56 sites in 1 country. Site status is shown where the registry gives one.
CH Amiens Hôpital Sud
Amiens, France · Recruiting
CHU Angers
Angers, France · Recruiting
CH Victor Dupouy
Argenteuil, France · Recruiting
Centre Hospitalier de la Côte Basque
Bayonne, France · Recruiting
Hôpital Jean Minjoz
Besançon, France · Recruiting
CH Beziers
Béziers, France · Recruiting
Hôpital Avicenne
Bobigny, France · Recruiting
CH Bordeaux
Bordeaux, France · Recruiting
Hôpital du Dr Duchenne
Boulogne-sur-Mer, France · Recruiting
Hôpital Morvan
Brest, France · Recruiting
CH Caen
Caen, France · Recruiting
Clinique du parc
Castelnau-le-Lez, France · Withdrawn
Centre Hospitalier René Dubos
Cergy-Pontoise, France · Recruiting
HIA Percy
Clamart, France · Recruiting
CHU Estaing
Clermont-Ferrand, France · Recruiting
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France · Recruiting
Hôpital Henri Mondor
Créteil, France · Recruiting
CHU de Dijon
Dijon, France · Recruiting
CH Dunkerque
Dunkirk, France · Recruiting
Hôpital Michallon
Grenoble, France · Recruiting
CH Versailles
Le Chesnay, France · Recruiting
CH Lens
Lens, France · Recruiting
CHRU de Lille, Hôpital Huriez
Lille, France · Recruiting
Hôpital St Vincent de Paul
Lille, France · Recruiting
CHU de Limoges
Limoges, France · Recruiting
Centre Leon Berard (CLB)
Lyon, France · Recruiting
CH Lyon Sud
Lyon, France · Recruiting
Marseille La Conception
Marseille, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
CH Meaux
Meaux, France · Recruiting
CHR Metz Thionville_Hôpital de Mercy
Metz, France · Recruiting
Hôpital Saint Eloi
Montpellier, France · Recruiting
CH Mulhouse
Mulhouse, France · Recruiting
CH Hôtel Dieu
Nantes, France · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
CHU Nice
Nice, France · Recruiting
CHRU de Nîmes
Nîmes, France · Recruiting
Hôpital Cochin
Paris, France · Recruiting
Hôpital La Pitié Salpêtrière
Paris, France · Recruiting
Hôpital Necker Enfants Malades
Paris, France · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.